Indication
Alzheimer's Disease Psychosis
3 clinical trials
4 products
Product
ACP-204Clinical trial
A 52-Week, Open-Label Extension Study of ACP-204 in Adults With Alzheimer's Disease PsychosisStatus: Not yet recruiting, Estimated PCD: 2029-04-01
Product
LY03017Product
LY03017-PlaceboClinical trial
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, SAD Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Oral LPM526000133 Fumarate Capsules (LY03017) in Healthy Adult Subjects.Status: Not yet recruiting, Estimated PCD: 2025-03-30
Clinical trial
A Master Protocol for Three Independent, Seamlessly Enrolling, Double-blind, Placebo-controlled Efficacy and Safety Studies of ACP-204 in Adults With Alzheimer's Disease PsychosisStatus: Recruiting, Estimated PCD: 2028-01-01
Product
Placebo